NDA – Discover Pharma

Welcome to Discover Pharma! Today is : October 14, 2026

NDA

Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
BridgeBio has secured FDA Priority Review for its oral infigratinib [...]

October 7, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Sagimet prepares Phase 3 acne trial for first US patients
Sagimet Biosciences is preparing to begin screening patients for its [...]

August 27, 2026
Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics
Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China
Adneuris Therapeutics has granted Zhejiang Conba Pharmaceutical exclusive rights to [...]

July 15, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Compass reports second positive Phase 3 trial of psilocybin therapy for treatment-resistant depression
Compass Pathways has reported positive six-month results from its second [...]

July 8, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
Abivax reports positive Phase 3 maintenance data for obefazimod in ulcerative colitis
Abivax has reported positive topline results from Part 2 of [...]

July 3, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK